NICE Publishes Final Recommendation for Almirall's Ilumetri (tildrakizumab) to Treat Moderate-To-Severe Plaque Psoriasis in Adults
Shots:
- NICE has recommended Ilumetri (tildrakizumab) as a cost-effective option for the treatment of adults patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy following its assessment submission in Aug’18
- Ilumetri (tildrakizumab) is evaluated in P-III reSURFACE 1 and 2 study in 1-800 patients > 200 sites across the globe resulted in maintaining PASI 75 in 9/10 patients @148wks. and >50% of patients reported no psoriasis after 3 doses- well tolerated with low SAEs & discontinuation rates
- Ilumetri (tildrakizumab) is a humanized immunoglobulin mAb inhibits IL-23 by binding to its p19 subunit and has received approval from the European Commission on Sep’18 and provisional approval from NICE on Mar 8- 2019
Ref: Almirall | Image: Blickfang Messebau GmbH
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com